Last updated: February 13, 2026
Overview of the Drug
The National Drug Code (NDC) 68094-0853 corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor developed by Bristol-Myers Squibb. Approved for multiple cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and others. The drug's mechanism involves blocking the PD-1 receptor on T-cells, enhancing immune response against tumors.
Market Size and Revenue Trajectory
The global oncology immunotherapy market was valued at approximately USD 55 billion in 2022 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 10% through 2028 [1].
Key indications for Nivolumab, including melanoma, NSCLC, and renal cell carcinoma, drive its revenue. In 2022, Bristol-Myers Squibb reported USD 5.4 billion in sales for Opdivo worldwide, marking its position as a leading immunotherapy agent [2].
Recent indications—such as combination treatments for bladder and gastric cancers—expand the eligible patient populations, increasing the potential market size.
Competitive Landscape and Market Share
The PD-1/PD-L1 inhibitor segment competes primarily with Pembrolizumab (Keytruda, Merck), Atezolizumab (Tecentriq, Roche), and Durvalumab (Imfinzi, AstraZeneca). In 2022, Opdivo's market share in US oncology sales was approximately 36%, trailing Keytruda at 50%, but surpassing Tecentriq and Imfinzi, which held 7% and 4%, respectively [3].
Patent exclusivity for Opdivo extends until at least 2030 in the US, though biosimilar development could challenge pricing sooner.
Pricing Structure and Cost Trends
In the United States, the average wholesale price (AWP) for Nivolumab is approximately USD 18,000 per 40 mg vial and USD 54,000 for an 80 mg vial, translating into significant treatment costs per patient.
Pricing dynamics exhibit the following trends:
-
Initial Launch Price: USD 1,000 per 40 mg vial (2009)
-
Current Avg. Price: USD 450 per mg (as of 2022), with variations based on payer negotiations and administration discounts.
-
Cost per Treatment Cycle: Varies by indication, typically USD 34,000-USD 50,000.
Reimbursement models, including Medicare and commercial payers, increasingly link prices to value-based assessments, potentially altering the pricing landscape.
Pricing Projections to 2030
Predicting drug prices involves analyzing patent status, competition, reimbursement policies, and drug adoption rates.
-
Patent expiry and biosimilar emergence could trigger price erosion starting 2028-2030, with estimates suggesting a 20-30% reduction in drug prices over five years post-biosimilar entry.
-
Value-based pricing models are expected to gain traction, emphasizing outcomes over volume, possibly stabilizing prices for high-value indications.
-
Market saturation and competitive pressures may push the average price downward by USD 2,000-USD 5,000 per vial annually once biosimilars are introduced and market competition intensifies.
-
European markets tend to see lower prices due to centralized healthcare negotiations, with current prices averaging USD 10,000-USD 15,000 per treatment cycle, which may influence U.S. prices via global pricing strategies.
Regulatory and Policy Factors
The Biden administration's efforts to control drug prices, including proposals for inflation-based rebates and increased transparency, could impact future pricing. The Inflation Reduction Act (IRA) of 2022 introduces provisions affecting Medicare drug pricing negotiations, which can influence longstanding price trajectories for drugs like Nivolumab.
Summary of Key Price Trends
| Year |
Approximate Price per 40 mg vial |
Notes |
| 2023 |
USD 18,000 |
Prices stabilized post-launch; high demand |
| 2025 |
USD 16,500 - USD 17,500 |
Slight decline anticipated due to negotiations |
| 2030 |
USD 12,600 - USD 15,000 |
Post-biosimilar market entry, increased competition |
Conclusion
The current market for Nivolumab is characterized by high-value sales driven by multiple indications, with growth expected to continue through 2028. Price erosion is likely post-patent expiry, especially if biosimilars gain approval in significant markets. Policy and reimbursement shifts may further influence future pricing, though high unmet needs and clinical efficacy sustain premium pricing levels.
Key Takeaways
-
Nivolumab (NDC 68094-0853) is a leading immunotherapy with USD 5.4 billion in global sales (2022).
-
Competition from Pembrolizumab and biosimilars could reduce prices by up to 30% by 2030.
-
Current U.S. price averages USD 18,000 per 40 mg vial, with treatment costs reaching USD 50,000+ per cycle.
-
Market growth driven by new indications and expanding patient populations.
-
Policy trends toward price regulation and value-based reimbursement may influence future pricing strategies.
FAQs
1. When are biosimilars for Nivolumab expected to enter the market?
Biosimilar applications are under review or approved in various regions, with approvals expected between 2024-2027. The first biosimilar in the U.S. is anticipated around 2028, aligning with patent expiry timelines.
2. How does market competition impact Nivolumab pricing?
Increased competition from biosimilars and other PD-1 inhibitors typically lead to price reductions, especially once biosimilar products gain market share.
3. What are the main factors influencing future Nivolumab prices?
Patent expiration, biosimilar approval, payer negotiations, reimbursement policies, and changing clinical guidelines all impact pricing trajectories.
4. Are there regional differences in Nivo pricing?
Yes, U.S. prices are generally higher than European or Asian markets due to differing pricing regulations and health system negotiations.
5. How might value-based pricing models affect Nivolumab?
If payers adopt outcome-based reimbursement, prices may be adjusted based on treatment efficacy, potentially leading to negotiated discounts or performance-based payments.
Sources
[1] Grandview Research, "Oncology Immunotherapy Market Size, Share & Trends Analysis," 2022.
[2] Bristol-Myers Squibb Annual Report 2022.
[3] IQVIA, "Pharmaceutical Market Tracking," 2022.
